



CFLAR Antibody

#24241

Catalog Number: 24241-1, 24241-2

Amount: 50µg/50µl, 100µg/100µl

Swiss-Prot No. : O15519

Form of Antibody: Rabbit IgG in phosphate buffered saline (without Mg²⁺ and Ca²⁺), pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol.

Storage/Stability: Store at -20°C/1 year


Immunogen: The antiserum was produced against synthesized peptide derived from Human CFLAR

Purification: The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.

Specificity/Sensitivity: CFLAR Antibody detects endogenous levels of total CFLAR

Reactivity: Human, Mouse, Rat

Applications: Predicted MW:52kd WB:1:500-2000 IHC:1:50-200



Western blot analysis of extracts of Jurkat cellines, using CFLAR antibody.

Background : Cellular FLIP (FLICE inhibitory protein) is a regulator of apoptosis that has various names, such as c-FLIP , Casper , CLARP , FLAME , I-FLICE , MRIT , CASH , and Usurpin . FLIP is expressed as two alternative splice isoforms, FLIP short (FLIPS) and FLIP long (FLIPL). FLIPS contains two death effector domains (DEDs) like those found on the death receptor adaptor protein FADD and the pro-domain of caspase-8. FLIPL shares significant homology with caspase-8 (FLICE), and contains an additional death effector domain, but FLIPL lacks the catalytic active site of the caspases and does not have protease activity. Both FLIP isoforms have been reported to interact with FADD and pro-caspase-8. The role of FLIP in apoptosis is controversial as some research studies have reported it to be anti-apoptotic, while others claim that it is pro-apoptotic. Overexpression of FLIPL can lead to caspase-8 heterodimers that produce an active protease, resulting in apoptosis. However, at physiological levels, it is thought that the binding of FLIP to the DED of FADD results in inhibition of caspase-8 processing. Reduction of FLIP by siRNA or gene targeting sensitizes cells to death receptor-mediated apoptosis. FLIP has also been implicated in the resistance of cancer cells to apoptosis and is upregulated in some cancer types including Hodgkin's lymphoma and ovarian and colon carcinomas .